INTRODUCTION
As the aging of the world ' s population becomes more pronounced, valid and reliable measures to assess situationspecifi c symptoms become an important research direction in order to identify the necessity of interventions, evaluate the impact of therapies and map a specifi c population on a particular set of problematic occurrences.
Both genders manifest, during the aging process, physical and psychological deterioration with several associated symptoms (including episodic sweating, memory and concentration Menopause Symptoms ' Severity Inventory (MSSI-38): assessing the frequency and intensity of symptoms Climacteric particular symptoms will occur, with their severity being associated with biopsychosocial factors [3] [4] [5] . As a result, menopausal symptoms vary greatly across cultures [6] [7] [8] .
Usually, women do not experience all menopausal symptoms; it is known that about 75% of postmenopausal women manifest some symptoms, experiencing them in an acute way. Moreover, different symptoms will have a dissimilar impact, ranging from mild discomfort to extreme distress 9 .
To evaluate these changes that emerge in midlife, several instruments have been designed to assess symptoms that occur during the climacteric period 1, 10, 11 , including some that were developed from previous scales 11 .
The measurement of menopause symptoms usually includes the evaluation of the presence of the symptoms, but should also include a self-rating assessment of their intensity or severity 12 . However, most of the available measures do not assess simultaneously the frequency and the intensity of each symptom; this would result in a more exact assessment of their severity level.
In order to identify an accurate severity of menopausal symptoms in peri-and postmenopausal women, an inventory, the Menopause Symptoms ' Severity Inventory-38 (MSSI-38) was developed to assess the frequency (how many times) and the intensity (how strong/intense) of each symptom. Some of the items included in this inventory are evidenced in the literature as changes that occur during the menopausal transition, but have been absent in previous menopausal scales and checklists. Some examples are the increase in facial hair, weight gain, breast tenderness, loss of head hair, changes in the skin (dryness or texture and tone alterations), as they can be identifi ed as secondary effects of hormone therapy 13 .
METHODS

Participants
After having given their informed consent and agreed to participate in the research, a community sample of 992 Portuguese women between 42 and 60 years completed all the instruments adequately (45 women were excluded due to incorrect completion).
The instruments included the MSSI-38, the Portuguese adaptation of the Depression, Anxiety and Stress Scales 14 , the Utian Quality of Life Scale 15 , and the Body Shape Questionnaire 16 , as well as a questionnaire to identify the menopausal status 17 and to explore sociodemographic, health and menopause-related characteristics. Participants formed a community sample mainly recruited through basic, middle and high schools, universities and corporate settings.
The menopausal status was defi ned according to Soules and colleagues 17 . Premenopausal women were identifi ed as not having any changes in their menstrual cycle. Perimenopausal women would report variable cycle length (more than 7 days different than usual), or had skipped two or more cycles and had an amenorrhea interval of more than 60 days. Women were confi rmed as being postmenopausal if they had at least a 12-month period of amenorrhea.
To improve the accuracy of the determination of menopausal status, in addition to the actual age, the age of the individual when the last menstrual period occurred was also requested. Table 1 describes the characteristics of the pre-, peri-and postmenopausal participants.
The Menopause Symptoms ' Severity Inventory-38
Item generation
A list of symptoms that could be manifested by peri-and postmenopausal women was compiled from different sources including menopause literature and pre-existing menopauserelated instruments 1, 10, 11 , the clinical experience of researchers, and the menopause-specifi c knowledge of three consultants (two gynecologists and one psychologist). Thirty-six semi-structured interviews were also conducted on the subject of menopause experience; these were later reviewed by two researchers to determine, amongst other things, additional symptoms or problematic occurrences.
Question format
For each symptom, participants were asked how frequent (how many times) and how intense (how strong) the symptom had been during the last month.
Responses were organized on a fi ve-point Likert-type scale (ranging from 0 to 4) for both frequency (that is, ' never ' , ' yes, less than once a week ' , ' yes, once or twice a week ' , ' yes, several times a week ' , and ' yes, daily or almost every day ' ) and intensity (namely, ' not intense ' , ' minimum intensity ' , ' moderate intensity ' , ' high intensity ' , or ' extreme intensity ' ).
Item reduction
After exploratory factor analysis, nine items from the initial 47 were eliminated: strong or fast heartbeat; diffi culty in sleeping; mood swings; feeling impatient towards others; fl atulence (gas) or pain caused by gas; dry skin; breast tenderness; diffi culty in urinating; and very strong and/or irregular vaginal bleeding. These items were excluded because they presented poor association with the factor to which they were predictably associated in the exploratory factor analysis, were absent in at least 50% of the sample, presented a kurtosis higher than 7 and a skewness higher than 3, or did not have an adequate internal consistency (this was the case of a 13th factor that compiled two items -breast tenderness and strong and/or irregular vaginal bleeding -which had a Cronbach ' s α of 0.40; composite reliability was also calculated for this factor but again it was very low, 0.51).
The fi nal structure included 38 symptoms, evaluated both in terms of frequency and intensity, and organized in 12 factors (anxiety; depressive mood; cognitive impairment; vasomotor symptoms; numbness; mouth, nails and hair changes; perceived loss of control; sexual symptoms; aches and pain; body shape; skin and facial hair changes; and urinary symptoms). 
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Statistical and psychometric analysis
To identify whether frequency scores were signifi cantly different from intensity scores, the data distributions of each symptom were compared using the Wilcoxon test for paired samples. Construct validity was asserted by factor analysis (exploratory and confi rmatory), convergent and discriminant validity. To explore the factor structure of the inventory, an exploratory factor analysis was made with PASW Statistics (v. 19.0, SPSS Inc., Chicago, IL, USA), using the principal components method and a varimax rotation. This analysis was made in 60% of the peri-and postmenopausal sample, randomly selected. To demonstrate the invariance of the measurement model, a confi rmatory factor analysis was conducted using AMOS software (v. 18.0, SPSS Inc., Chicago, IL, USA).
The convergent validity of the inventory was analyzed through the average variance extracted (AVE). An adequate value should be higher than 0.50 18 . This discriminant validity was explored comparing the squared correlation of interfactors with the AVE of each individual factor. In order to have discriminant validity, the association between factors should be smaller than the individual AVE 18 .
Criterion validity was explored through concurrentoriented validity of some scales, using Pearson ' s correlation with similar constructs. To test this, three other subscales were used, namely, the Depression, Anxiety and Stress Scales (DASS) 14 , the Utian Quality of Life Scale for sexual quality of life 15 and the Body Shape Questionnaire (BSQ) 16 .
In addition, to demonstrate that the measure was adequate in assessing symptoms that occur during menopause (that is, during the menopausal transition and postmenopause), the invariance of the measurement model was tested by integrating, in the analysis, women who were not in the menopause phase (premenopausal participants), and therefore were not expected to have menopausal symptoms. This analysis had the purpose of proving that the measurement model would be variant when using a group of women who were not in menopause.
Reliability was studied applying the Cronbach ' s α , and sensitivity was explored through the analysis of minimum and maximum values, skewness and kurtosis. Values are expected to range from 0 to 4 and skewness and kurtosis are expected to have values below 3 and 7 respectively, while reliability scores should be above 0.70 18 .
To evaluate whether age could function as a moderator for the impact of menopausal status over the symptoms, a structural model was built to evaluate a possible interaction effect with the 12 symptoms.
Finally, to explore whether there are signifi cant differences between women in peri-and postmenopause, regarding the 12 sets of symptoms, a one-way ANOVA was applied. For personal use only. 
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RESULTS
Frequency and intensity
To confi rm whether the frequency was signifi cantly different from the intensity measurement, the frequency and intensity of every item (or symptom) were compared with the Wilcoxon test for paired samples. As evidenced in Table 2 , there are signifi cant differences between the measurement of frequency and intensity, for most symptoms.
To analyze the psychometric qualities of the measures assessed by the inventory, construct-related and criterion validity were evaluated for each factor. Moreover, reliability, sensitivity and measurement invariance, in two independent samples, were also explored. The severity of each symptom is given by the mean of the frequency and intensity for that symptom. Climacteric 147
Construct validity
Factorial validity
The exploratory factor analysis was performed, using PASW Statistics (v. 19.0), on 60% of the randomly selected data, from the total sample of peri-and postmenopausal women. Factors extracted were those with an eigenvalue greater than 1 and theory-supported. The best-fi t solution was a 12-factor structure, excluding nine items from the original inventory. The sampling adequacy was confi rmed by the Kaiser -MeyerOlkin test (KMO ϭ 0.938) and the total variance explained by this 12-factor structure is 73.0%. Table 3 presents the range of loadings of all symptoms that compose each one of the 12 factors.
Convergent validity
All subscales present good AVE scores (i.e. Ͼ Ϫ 0.50) except for the mouth, nails and hair changes (0.41) and perceived loss of control (0.38) subscales.
Discriminant validity
Of the possible comparisons for the 66 paired-factors, for the existent 12 factors, 57 presented good discriminant validity. The nine exceptions with low discriminant validity were the following pairs: depressive mood and cognitive impairment; cognitive impairment and aches/pain; depressive mood and anxiety; aches/pain and numbness; skin, facial hair changes and body shape; depressive mood and perceived loss of control; aches/pain and perceived loss of control; mouth, nails and hair changes and perceived loss of control; and anxiety and perceived loss of control.
Criterion validity
MSSI-38 ' s anxiety subscale was highly related with DASS ' s anxiety factor ( r p ϭ 0.617; p Ͻ 0.001). In addition, MSSI-38 ' s depressive mood was also strongly associated with DASS' s depression subscale ( r p ϭ 0.736; p Ͻ 0.001). The association between sexual quality of life and sexual symptoms was both negative and signifi cant ( r p ϭ Ϫ0.221; p Ͻ 0.001), as expected. Finally, MSSI-38 ' s body shape was also correlated with the total of BSQ ( r p ϭ 0.557; p Ͻ 0.001).
Multi-group analysis
Invariance analysis
The model presents a good adjustment ( χ 2 /d.f. ϭ 2.055; comparative fi t index (CFI) ϭ 0.895; goodness-of-fi t index (GFI) ϭ 0.830; root mean square error of approximation (RMSEA) ϭ 0.039, p ϭ 1.000, 90% confi dence interval (CI) 0.037 -0.041) in both groups (60% and 40% of the sample of peri-and postmenopausal women).
The unconstrained measurement model does not have a signifi cantly better fi t than the model with constrained factorial weights ( χ 2 (26) ϭ 27.229; p ϭ 0.397), hence confi rming the invariance of the measurement model. Therefore, there are no signifi cant differences in the factorial measurement weights between both groups (60% of the sample vs. 40%), confi rming the assessment ' s stability of the 12 constructs comprised in the MSSI-38.
Pre-vs. peri-vs. postmenopausal participants
This measure also presented a good adjustment to the global sample, that is, 992 women in pre-, peri-and postmenopause ( χ 2 /d.f. ϭ 3.415; CFI ϭ 0.923; GFI ϭ 0.901; RMSEA ϭ 0.049, p ϭ 0.735; 90% CI 0.047 -0.051). As expected, when women in premenopause are included, the measurement weights are signifi cantly different ( χ 2 (52) ϭ 82.208; p ϭ 0.005), supporting the variance of the measure in the groups. However, and again as expected, if only peri-and postmenopausal women are considered, the constrained measurement model does not have a signifi cantly better adjustment than the unconstrained one ( χ 2 (26) ϭ 30.448; p ϭ 0.249). These results support the inventory ' s stability as a measure for menopausal symptoms that are observed in peri-and postmenopausal women ( χ 2 / df ϭ 2.131; CFI ϭ 0.888; GFI ϭ 0.827; RMSEA ϭ 0.040, p ϭ 1.000; 90% CI 0.038 -0.042).
Reliability
The internal consistency of these 12 subscales was also explored. All subscales presented an acceptable Cronbach ' s α , as shown in Table 4 . 
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Sensitivity
To address sensitivity, the range of the Likert-type scale was explored as well as the skewness and kurtosis values for the severity of all symptoms, as shown in Table 5 . In addition, to evaluate the sensitivity of the subscales, minimum and maximum values, as well as skewness and kurtosis, were explored for the severity of the 12 sets of symptoms, as shown in Table 6 .
Symptom severity in peri-vs. postmenopausal participants
A structural model was built to explore whether age was a confounding variable. The results showed that there is a negative and signifi cant interaction in two sets of symptoms. This means that, for both skin and facial hair changes ( β ϭ Ϫ0.183; p ϭ 0.028) and vasomotor symptoms ( β ϭ Ϫ0.228; p ϭ 0.001), age moderates the effect of menopausal status over these two sets of symptoms.
The mean severity was calculated for each subscale, for periand postmenopausal participants separately, and a Student t -test was used to analyze whether both groups diverged signifi cantly in the 12 groups of symptoms, as observed in Table 7 .
DISCUSSION
Patient-reported outcomes are useful not only in the context of research but also in clinical settings, as they allow the identifi cation of psychological and physical symptoms that might be unobserved, and permit the monitoring of the evolution of symptoms and exploration of pertinent information regarding the implemented treatment 19 . Specifi cally for menopause, the literature evidences the importance of the availability of indexes that cover both menopausal symptoms and the potential side-effects of hormone therapy 20 .
Some of the nine excluded items have received some attention in the menopause literature. Specifi cally, diffi culty in sleeping has been associated with vasomotor symptoms and psychosocial factors 21, 22 . This was not found in the present research, given that this particular item was never associated with the vasomotor symptom scale. The low severity of vasomotor symptoms in this community sample might partially explain the absence of this association.
Dysuria (diffi culty in urinating) was also excluded, although there was clearly a factor compiling urinary symptoms (which was kept due to its good psychometric characteristics and theoretical sustainability) with which this item was never related. This may evidence that dysuria is not an observed urinary symptom in this sample of peri-and postmenopausal women.
The poor discriminant validity between some subscales, namely between perceived loss of control and depressive mood, anxiety, aches and pain, mouth, nails and hair changes, might evidence that some psychological and physical symptoms may enhance the perception of decreased control.
Breast tenderness and very strong and/or irregular vaginal bleeding, although being related to hormonal changes 23 and the side-effects of hormone therapy 24 , and therefore important items to include in a menopausal symptoms scale, showed, in this study, a very low internal consistency. As a result, this factor was not included in the fi nal version of the inventory.
The MSSI-38 provided data with good psychometric properties. Thus, the MSSI-38 may be used to accurately measure the severity of menopause symptoms, considering both the frequency and intensity of each symptom. The inclusion of these two evaluation elements is important, given that the times a symptom occurs (frequency) and the intensity (how intense/strong) of the symptom are two signifi cantly different ways of evaluating it, as shown above. As analyzed, 30 of the 38 symptoms presented statistically signifi cant differences between their frequency and intensity measurements.
In addition, it was also shown that the frequency assessment of the symptoms presents higher means when compared with intensity: except for item 3, ' panic attacks ' (where frequency is lower than intensity) and items 7, ' crying spells ' , and 18, ' headache ' (which present an equal mean frequency and intensity), all symptoms are more frequent than intense. Hence, studies considering only intensity may obtain lower levels of reported symptoms than those assessing the frequency of each symptom. This conclusion is supported by a prior study 25 regarding the vasomotor symptoms: although 57% of women in their study reported hot fl ushes, only 9% considered these to be bothersome. Likewise, night sweats were manifested by 36% of participants; however, only 6% considered them to be troublesome.
The MSSI-38 allows the measurement of 12 types of symptoms, of both physical and psychological nature. Thus, it allows the calculation of 12 distinct indexes of symptom severity, corresponding to the 12 subscales of this instrument.
Results show that the mean severity of symptoms is low (ranging from 0.4 to 1.4 in a scale from 0 to 4) in both peri-and postmenopausal women. This supports the idea that the great majority of women in this community sample do not present a high severity of menopausal symptoms. This is congruent with For personal use only. a previous study 26 which concluded that, although menopausal symptoms are common in middle-aged women, they are usually not perceived as problematic. Also, it has been concluded that a higher educational level is associated with less complaints of symptoms 21, 27 ; given that a large number of participants had a university degree (specifi cally, 37% of the total sample), this might also explain the low severity of menopausal symptoms reported. However, there is also the possibility that the self-report methodology has resulted in an under-report of the symptoms; as examined elsewhere 28 , highly symptomatic participants under-reported the number of objective (physiological) hot fl ushes by 43%.
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Nevertheless, the low severity of symptoms might be due to the fact that this is a community and not a clinical sample. The use of a community sample in this study aimed to overcome a limitation that is usually seen in menopausal research which is the fact that many studies use clinical samples, thus excluding the extrapolation to a non-clinical population 29 .
Moreover, most women in this research were not taking hormonal therapy or herbal/soy products to decrease menopausal symptoms (90% and 73.2% of peri-and postmenopausal women, respectively, did not take any medicine or supplement to manage menopausal symptoms); thus, the probability of the symptoms being under-reported due to medication is Climacteric Downloaded from informahealthcare.com by University College London on 09/05/12
For personal use only. Climacteric diminished. However, the possibility that the subgroup of women taking hormone therapy (or herbal/soy therapy) may have reported lower levels of symptoms than they would have if therapy was not being used, cannot be discarded.
An increase in symptom reporting is usually expected during the progression through the menopausal stages 27 . Melby, Lock and Kaufert 30 showed that, although symptom reporting during premenopause is consistently lower, when compared with peri-and postmenopause phases, it is still not unanimous in which one of the two latter menopausal stages (peri-or postmenopause) higher rates of symptoms are reported. Regarding hot fl ushes, their prevalence has been evidenced as higher in post-than in perimenopausal women: 37% of pre-, 48% of early peri-, 63% of late peri-and 79% of postmenopausal women have reported these vasomotor symptoms in previous research 31 . Guthrie and colleagues 32 have also concluded that the presence of higher rates of bothersome hot fl ushes is observed 2 years after the fi nal menstrual period. However, this conclusion it is not unanimous, since some authors have verifi ed a decrease in menopausal symptoms from peri-to postmenopause 33 , or found perimenopausal women more prone than their counterparts in pre-and postmenopause to experience aches and pains (head, back or joint); however, vasomotor symptoms were more prevalent in postmenopause, remaining high in this stage 34 .
In this research, although no analysis was made in terms of comparing early with late perimenopause; the differences between women in menopausal transition (perimenopause) and postmenopause are not signifi cant in all symptoms. The symptoms that increase signifi cantly are eminently physical (aches and pains, vasomotor symptoms, numbness, skin and facial hair changes, urinary and sexual symptoms). Psychological symptoms such as depressive mood, anxiety and perceived loss of control, do not increase signifi cantly from menopausal transition to postmenopause. This conclusion is congruent with a previous study which found that postmenopausal women do not present a higher prevalence of psychological symptoms, reporting only more hot fl ushes and night sweats 4 .
The same research, when comparing women in pre-and postmenopause, did not fi nd signifi cant differences in the occurrence of the vast majority of symptoms (anxiety, depression, somatic and sexual symptoms did not diverge between the two groups) 4 . However, the present research evidences that, when comparing women in premenopause with participants in menopausal transition and postmenopause, differences in symptom measurements are observed, indicating different measurement weights according to the menopausal status.
Memory functioning has also been observed to be decreased in perimenopausal women when compared with their postmenopausal counterparts 35 . This was not observed in the present sample given that there are no signifi cant differences in cognitive impairment (which encompasses a memory selfreported assessment) between peri-and postmenopausal women. 
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The results also show that age moderates the effect of menopausal status over two types of symptoms (vasomotor and skin and facial hair changes). Since the interaction is negative, the impact of menopausal status on the symptoms is suppressed by age. Therefore, as age progresses, vasomotor symptoms and changes in skin and facial hair are infl uenced less by menopausal status. Similar conclusions have been mentioned in the literature, namely, that somatic symptoms of menopause are negatively and signifi cantly related with age progression 36 and also that skin changes are observed in the aging process 37 .
Although the MSSI-38 was applied to women from 42 to 60 years old, it is believed that this instrument will also be useful in assessing postmenopausal symptoms in women older than 60. Further research with this age group and other ethnicities and cultures is recommended, since this is a mostly Caucasian Portuguese sample.
In conclusion, the Menopausal Symptom Severity Inventory-38 is an instrument with good psychometric properties that assesses menopausal symptoms, both in frequency and intensity, in order to obtain an accurate degree of symptom severity. This inventory has been proven to have factorial, convergent and discriminant validity. Moreover, criterion validity for some scales as well as a good reliability and sensitivity for all scales has been shown. More studies are needed to confi rm this structure with other samples (for example, clinical ones, given that this inventory was generated in a community sample) and cultures (since there is evidence that cultural and ethnical differences may infl uence the menopause experience).
